Informations générales (source: ClinicalTrials.gov)
Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin
Interventional
Phase 4
GERCOR - Multidisciplinary Oncology Cooperative Group (Voir sur ClinicalTrials)
octobre 2005
29 juin 2024
RATIONALE: Learning about the relationship between platinum levels in the blood and
neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help
patients live more comfortably.
PURPOSE: This phase IV trial is studying the relationship between platinum levels in the
blood and neurotoxicity in patients who are receiving oxaliplatin for gastrointestinal
cancer.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital La Pitié-Salpêtrière | Jean-Baptiste Meric, MD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Saint Antoine | Olivier Rosmorduc, MD, PhD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Tenon | Thierry Andre, MD | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Hospital Universitaire Hop Huriez - 59037 - Lille - France | Mohamed Hebbar, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU de Grenoble - Hopital Michallon - 38043 - Grenoble - France | Christine Rebischung | Contact (sur clinicalTrials) | |||
| Clinique Saint Jean - 69008 - Lyon - France | Gerard Lledo | Contact (sur clinicalTrials) | |||
Critères
Tous
DISEASE CHARACTERISTICS:
- Diagnosis of gastrointestinal cancer
- Receiving or planning to receive 8 months of oxaliplatin-based chemotherapy
- No pre-existing neuropathy
- No CNS disease or cerebral metastases
PATIENT CHARACTERISTICS:
- WHO 0-1
- Life expectancy ≥ 12 weeks
- No biliary or gastro-duodenal obstruction
- No familial, social, geographical, or psychological condition that would preclude
study treatment
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No other concurrent drug or agent that is potentially neurotoxic
- Diagnosis of gastrointestinal cancer
- Receiving or planning to receive 8 months of oxaliplatin-based chemotherapy
- No pre-existing neuropathy
- No CNS disease or cerebral metastases
PATIENT CHARACTERISTICS:
- WHO 0-1
- Life expectancy ≥ 12 weeks
- No biliary or gastro-duodenal obstruction
- No familial, social, geographical, or psychological condition that would preclude
study treatment
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No other concurrent drug or agent that is potentially neurotoxic